gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab
astellas,seagen,merck
['pembro', 'ev-103']
 nearly 4-yr f/u of ev-103 cohort a phib/ii (n=45) #ev + pembro in #1l cis-ineligible adv/muc: orr by bicr 73.3% (cr 15.6%), median os 26.1 mos, dor 22.1 mos. no new safety concerns that have emerged, most common #2l was pembro &amp; carbo-based chemo #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope